KANATA, Ontario--(BUSINESS WIRE)-- BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business’ mission to deliver high-quality nuclear medical products and solutions that
2Q24 revenues of $681.5 million 2Q24 net income of $73.0 million, adjusted EBITDA (1) of $126.2 million 2Q24 diluted GAAP EPS of $0.79, non-GAAP (1) EPS of $0.82 BWXT-led JV awarded management and operations contract for the NNSA’s Pantex Plant 2024 non-GAAP EPS (1) guidance revised to
Multi-year supply agreement for radium-226 processing and purification Collaboration will work to provide Ac-225 for clinical trials and commercial supply OTTAWA, Ontario & BELOIT, Wis.--(BUSINESS WIRE)-- BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc.
LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (NYSE: BWXT) will issue a press release detailing second quarter 2024 results on Monday, August 5, 2024, after market close and will host a conference call at 5:00 p.m. EDT. Listen-only participants are encouraged to participate and view the
Support Strong Among Wyoming Stakeholders and Potential Vendors During Phase One of Cost-Share Program LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (NYSE: BWXT) today announced the award of the second phase of a contract with the Wyoming Energy Authority to assess the viability of
LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (NYSE: BWXT) today announced a contract award from the U.S. Department of Energy, National Nuclear Security Administration (DOE/NNSA) for management and operations of the Pantex Plant. Following an initial term of five years, NNSA has the
OTTAWA, Ontario--(BUSINESS WIRE)-- BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient. Ac-225 is an alpha-emitting isotope used in targeted alpha therapies
1Q24 revenues of $604.0 million 1Q24 net income of $68.5 million, adjusted EBITDA (1) of $115.2 million 1Q24 diluted GAAP EPS of $0.75, non-GAAP (1) EPS of $0.76 Announced expansion of Cambridge manufacturing plant; enhancing capabilities to serve the global CANDU and Small Modular Reactor markets
SMR Supplier Group Will Support Global Deployment of BWRX-300 Design CAMBRIDGE, Ontario--(BUSINESS WIRE)-- BWXT Canada Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), has been selected as the first qualified supply chain company to join the GE Vernova nuclear business’ supplier group
C$80 million investment will create more than 200 new jobs in Ontario One of North America’s largest commercial nuclear manufacturers to get even bigger, driven by increasing demand for clean nuclear energy CAMBRIDGE, Ontario--(BUSINESS WIRE)-- BWX Technologies, Inc.